NERV - Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of candidate products for the treatment of diseases of the central nervous system. The company is headquartered in Waltham, Massachusetts.

52W High

$3.00

52W Low

$1.15

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.27

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

1.59

Forward P/E (<15 better)

11.21

EV/EBITDA (<8 favorable)

0.11

EV/Revenue (<3 favorable)

0.03

P/S (TTM) (<3 favorable)

1.87

P/B (<3 favorable)

2.68

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

22.26%

Institutions (25–75% balanced)

27.99%

Shares Outstanding

6,993,400

Float

5,437,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

-6,531,288

EPS (TTM)

1.48

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-6.75%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0366

0.0448

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025